Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) has a beta value of 1.11 and has seen 1,650,491 shares traded in the recent trading session. The company, currently valued at $18.01 Billion, closed the recent trade at $78.5 per share which meant it gained $1.9 on the day or 2.48% during that session. The HZNP stock price is -1.73% off its 52-week high price of $79.86 and 69.67% above the 52-week low of $23.81. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.1 Million shares traded. The 3-month trading volume is 2.49 Million shares.
The consensus among analysts is that Horizon Therapeutics Public Limited Company (HZNP) is a Buy stock at the moment, with a recommendation rating of 1.7. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 1 out of 11 have rated it as a Hold, with 10 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is $0.93.
Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) trade information
Sporting 2.48% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Sep 15 when the HZNP stock price touched $79.87- or saw a rise of 0.84%. Year-to-date, Horizon Therapeutics Public Limited Company shares have moved 118.78%, while the 5-day performance has seen it change 13.63%. Over the past 30 days, the shares of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) have changed 8.76%. Short interest in the company has seen 4.08 Million shares shorted with days to cover at 1.64.
Wall Street analysts have a consensus price target for the stock at $100.91, which means that the shares’ value could jump 28.55% from current levels. The projected low price target is $80 while the price target rests at a high of $123. In that case, then, we find that the current price level is +56.69% off the targeted high while a plunge would see the stock lose 1.91% from current levels.
Horizon Therapeutics Public Limited Company (HZNP) estimates and forecasts
Figures show that Horizon Therapeutics Public Limited Company shares have outperformed across the wider relevant industry. The company’s shares have gained +192.59% over the past 6 months, with this year growth rate of 45.88%, compared to 13.7% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 45.3% and 92.9% for the next quarter. Revenue growth from the last financial year stood is estimated to be +47%.
9 analysts offering their estimates for the company have set an average revenue estimate of $511.14 Million for the current quarter. 9 have an estimated revenue figure of $579.07 Million for the next quarter concluding in December 01, 2020. Year-ago sales stood $329.76 Million and $363.55 Million respectively for this quarter and the next, and analysts expect sales will grow by 55% for the current quarter and 59.3% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +23.9% over the past 5 years. Earnings growth for 2020 is a modest +736.3% while over the next 5 years, the company’s earnings are expected to increase by 28.8%.